Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.69 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL995085 | 0.87 | GAA (0.77) | GAASMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL7161487 | 0.87 | P2RX1 (0.62) | GAASMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL4958310 | 0.86 | GAA (0.71) | GAASMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL27657640 | 0.86 | GAA (0.71) | GAASMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL4958300 | 0.86 | GAA (0.71) | GAASMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL94829 | 0.86 | GAA (0.71) | GAASMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL27965076 | 0.86 | MEN1 (0.53) | GAASMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL5226448 | 0.85 | MAPT (0.78) | GAASMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL30236947 | 0.85 | MAPT (0.78) | GAASMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL6814805 | 0.85 | GAA (0.69) | GAASMN1; SMN2HTTNCOA1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2269988-B1 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2012-05-23 | — | — | EP | disclosed |
| EP-1446381-B1 | ANTHRANILIC ACID AMIDES AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| EP-2269988-A2 | Anthranilic acid amides and pharmaceutical use thereof | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| CN-100467450-C | Anthranilamides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2009-03-11 | — | — | CN | disclosed |
| EP-1014962-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2007-06-27 | — | — | EP | disclosed |
| US-7067543-B2 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2006-06-27 | — | — | US | disclosed |
| CN-1578768-A | Anthranilamides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2005-02-09 | — | — | CN | disclosed |
| US-20040248947-A1 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
| EP-1446381-A1 | ANTHRANILIC ACID AMIDES AND PHARMACEUTICAL USE THEREOF | Novartis AG (CH) | 2004-08-18 | — | — | EP | disclosed |
| US-6605626-B2 | Benzamide inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-08-12 | — | — | US | disclosed |
| WO-2003040101-A1 | ANTHRANILIC ACID AMIDES AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2003-05-15 | — | — | WO | disclosed |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | BEIGHT DOUGLAS WADE (US) | 2002-08-29 | — | — | US | disclosed |
| US-6313122-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
| EP-1014962-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999000121-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248947-A1 | Anthranilic acid amides and pharmaceutical use thereof | AFF1, FFAR1, FFAR2 | GAA 3110/4885SMN1; SMN2 2170/4885HTT 1752/4885 |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | TFPI, F11, F12 | GAA 77/4885SMN1; SMN2 2752/4885HTT 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.